Atlas Trials

Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.

Clinical trial NCT05249959 · RECRUITING

Trial details

NCT number
NCT05249959
Sponsor
Fondazione Italiana Linfomi - ETS
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Relapsed Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
Start date
2022-03-21
Primary completion
2026-03-21
Enrollment
49

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.